Wells Fargo & Company Tenaya Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 24,315 shares of TNYA stock, worth $53,979. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,315

Previous 22,421 8.45%

Holding current value

$53,979

Previous $69,000 33.33%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.93 - $3.99 $3,655 - $7,557	1,894 Added 8.45%	24,315 $46,000
Q2 2024 Aug 13, 2024	BUY	$2.72 - $4.99 $16,281 - $29,870	5,986 Added 36.42%	22,421 $69,000
Q1 2024 May 10, 2024	BUY	$2.88 - $6.8 $6,189 - $14,613	2,149 Added 15.04%	16,435 $85,000
Q4 2023 Feb 09, 2024	BUY	$1.73 - $3.39 $5,169 - $10,129	2,988 Added 26.45%	14,286 $46,000
Q3 2023 Nov 13, 2023	SELL	$2.55 - $5.65 $15,468 - $34,272	-6,066 Reduced 34.93%	11,298 $28,000
Q2 2023 Aug 15, 2023	BUY	$2.64 - $7.64 $25,689 - $74,344	9,731 Added 127.49%	17,364 $101,000
Q1 2023 May 12, 2023	BUY	$1.92 - $3.59 $14,655 - $27,402	7,633 New	7,633 $21,000
Q3 2022 Nov 14, 2022	SELL	$2.9 - $5.88 $638 - $1,293	-220 Reduced 86.61%	34 $0
Q2 2022 Aug 12, 2022	SELL	$5.01 - $14.12 $87,309 - $246,069	-17,427 Reduced 98.56%	254 $1,000
Q1 2022 May 16, 2022	SELL	$9.41 - $19.3 $9,325 - $19,126	-991 Reduced 5.31%	17,681 $208,000
Q4 2021 Feb 14, 2022	BUY	$18.41 - $29.58 $342,333 - $550,040	18,595 Added 24149.35%	18,672 $354,000
Q3 2021 Nov 15, 2021	BUY	$15.35 - $26.66 $1,181 - $2,052	77 New	77 $2,000

Others Institutions Holding TNYA

# of Institutions

Shares Held

56.3M

Call Options Held

900

Put Options Held

400

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $91.8M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Tenaya Therapeutics, Inc. Transaction History